Top

A -- Biomedical and Pharmaceutical Application of Accelerator Mass Spectrometry

Active

Reference-Number-FBO02-004-291Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Lawrence Livermore National Laboratory (LLNL), managed by the University of California for the U.S. Department of Energy, is inviting industrial partners to license and commercialize its patented accelerator mass spectrometry (AMS) technologies tailored for biomedical and pharmaceutical applications. These technologies offer advanced capabilities for the quantitative analysis of elemental compositions within biomedical samples, particularly enabling the detection of low-level radioactive isotopes such as tritium (3H) and carbon-14 (14C) with high sensitivity, surpassing the limits of existing commercial detection methods. This allows for precise metabolic kinetic studies of pharmaceutical compounds, providing unique research and development advantages in the industry. LLNL holds broad patent rights for these applications in the U.S. and Canada and is prepared to support selected partners with technology transfer including sample characterization, preparation, and data systems. The announcement is not a procurement but a call for companies with proven market delivery capabilities to submit a written statement of interest, including a commercialization plan and corporate qualifications, within 45 days of the notice. Interested parties must contact LLNL's Industrial Partnerships and Commercialization office to express their interest and discuss potential licensing arrangements for these innovative AMS technologies. This opportunity aims to facilitate the introduction of cutting-edge biomedical analytical techniques into the commercial marketplace through collaborative partnerships.

General Info

LLNL invites partners to license advanced AMS technology for biomedical isotope detection and commercialization.

Agency

N/A

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PostedMar 4

special-notice

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyN/A

ContactsNo contacts available

OfficeN/A

Organization / Agency

N/A

Office AddressN/A

ContactsNo contact information available

Full Description

LAWRENCE LIVERMORE NATIONAL LABORATORY SEEKS PARTNERSHIPS WITH INDUSTRY TO COMMERCIALIZE ITS INVENTION IN BIOMEDICAL AND PHARMACEUTICAL APPLICATION OF ACCELERATOR MASS SPECTROMETRY Announcement: Lawrence Livermore National Laboratory (LLNL), operated by the University of California under contract with the U.S. Department of Energy (DOE), is seeking industrial partners to commercialize LLNL's patent technologies on biomedical and pharmaceutical applications of accelerator mass spectrometry (AMS). Broad patent positions are held on such applications in both US and Canada. The patent technologies enable quantitative analysis of elemental composition of biomedical samples. In particular, the technologies allow the detection of low level radioactive trace elements, such as 3H and 14C, as long as the trace element concentration is about one hundred times higher than the background. With AMS, the patent technologies enable accurate study of metabolic kinetics of pharmaceutical compounds that can not be achieved by other commercially available detection methods. More detailed information on the technology can be found in US patents 5,376,355, 5,366,721, and 5,209,919. LLNL wants to license the technology to industrial partners that have demonstrated capability to deliver the technologies to the market. With a suitable arrangement, LLNL intends to provide industrial partners corresponding technologies such as complete sample characterization, sample preparation, and data acquisition and logging systems. Note: THIS IS NOT A PROCUREMENT. Companies interested in commercializing LLNL's Biomedical and Pharmaceutical Application of Accelerator Mass Spectrometry should provide a written statement of interest including a commercialization plan and a description of corporate capabilities relevant to commercializing the technology. Written responses should be directed to: Lawrence Livermore National Laboratory Industrial Partnerships and Commercialization P.O. Box 808, L-795 Livermore, CA 94551-0808 Attention: FBO02-004/291. Please provide your written statement within forty-five (45) days from the date this announcement is published to ensure consideration of your interest in LLNL's Biomedical and Pharmaceutical Application of Accelerator Mass Spectrometry

Similar Contracts

Same NAICS industry code